| Methods |
7‐day washout period; total 4‐week single‐blind placebo run‐in, patients' supine DBP >/= 95 mm Hg after initial 2‐week single‐blind placebo phase; additional 2‐week single‐blind placebo phase; inclusion criteria= mean supine DBP 100‐115 mm Hg, and two BP readings during weeks 2 and 4 of single‐blind placebo phase could not differ by > 7 mm Hg; 8‐week double‐blind treatment |
| Participants |
Losartan 10 mg: n=80(51 males,29 females); median age=55 years; baseline SBP=160.7 mm Hg, DBP=104.3 mm Hg;
Losartan 25 mg: n=82(55 males,27 females); median age=53 years; baseline SBP=158.7 mm Hg, DBP=103.3 mm Hg;
Losartan 50 mg: n=79(53 males,26 females); median age=53 years; baseline SBP=158.3 mm Hg, DBP=104.1 mm Hg;
Losartan 100 mg: n=90(59 males,31 females); median age=52.5 years; baseline SBP=156.3 mm Hg, DBP=104.1 mm Hg;
Losartan 150 mg: n=84(62 males,22 females); median age=56 years; baseline SBP=158.6 mm Hg, DBP=103.4 mm Hg;
Placebo: n=78(47 males,31 females); median age=53 years; baseline SBP=157.9 mm Hg, DBP=103.3 mm Hg |
| Interventions |
Losartan 10 mg once daily;
Losartan 25 mg once daily;
Losartan 50 mg once daily;
Losartan 100 mg once daily;
Losartan 150 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP;
Mean change from baseline in peak supine SBP/DBP;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP reported; endpoint SD not reported, BP data from Table 2, p.1348; BP measurement device not reported; Jadad score=3; funding source= Merck |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
